New hope for psoriasis patients when old treatments fail
NCT ID NCT07449234
Summary
This study observes patients with moderate-to-severe psoriasis who are switching from one biologic medication (ustekinumab) to another (guselkumab) in regular clinical practice. Researchers will track 200 patients for one year to see how well the new treatment controls their skin symptoms and improves their quality of life. The goal is to gather real-world evidence about the safety and effectiveness of this treatment switch.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
LKH-Univ. Klinikum Graz
RECRUITINGGraz, 8036, Austria
Conditions
Explore the condition pages connected to this study.